Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study

Ähnliche Einträge

• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  von: Soo Lim, et al.
  Veröffentlicht: (2024)
• Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
  von: Kyung Ah Han, et al.
  Veröffentlicht: (2024)
• Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
  von: Da Hea Seo, et al.
  Veröffentlicht: (2025)
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  von: Tae Seo Sohn, et al.
  Veröffentlicht: (2024)
• EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes ; randomized, placebo‐controlled, double‐blind, multicentre trial ( CANNA study)
  von: Ji Eun Jun, et al.
  Veröffentlicht: (2025)